Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination

A composition and analog technology, applied in the field of combination, can solve the problem of no medicine for Huntington's disease

Pending Publication Date: 2022-04-29
GENESIS PHARMA SA
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There are currently only two drugs (riluzole and edaravone) approved to slow (albeit modestly) the progression of ALS, and there are no approved treatments for Huntington's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination
  • Combination
  • Combination

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0623] Example 1. Dose Effect Study of the Efficacy of Exenatide, Canrenoate Potassium and Glibenclamide and Their Combinations in the Rat Model of Cerebral Ischemia and Reperfusion Injury

[0624] The aim of this study was to evaluate (a) the neuroprotection of glibenclamide, exenatide and canrenoate potassium in a rat model of cerebral ischemia and reperfusion injury after repeated intravenous administration as monotherapy Dose Effect of Effects (Study Part I) and Effect of (b) Compound Combination Compared to the Corresponding Monotherapy (Study Part II).

[0625] Transient middle artery occlusion (t-MCAO) was performed according to the method described by R. Schmid-Elsaesser et al. (Stroke. 1998; 29(10): 2162-70). Test compounds were administered intravenously 20 minutes prior to reperfusion and then twice daily for six consecutive days thereafter. On Study Day 2 (one day after surgery) and Study Day 7 (7 days after surgery and before study termination), the altered Neuro...

Embodiment 2

[0653] Example 2. Efficacy study of the combination of exenatide, canrenoate potassium and glibenclamide in a rat model of vascular dementia

[0654] The chronic cerebral hypoperfusion model in Wistar rats induces brain damage in the rat brain by permanently occluding both common carotid arteries, which also causes cognitive deficits. This model is similar to that of vascular dementia, and the technique can reduce blood flow by as much as 40% to 80% for several months in the cerebral cortex and hippocampus, which induces certain learning disabilities.

[0655] Research purposes

[0656] The aim of this study was to evaluate the neuroprotective efficacy of the combination of exenatide, canrenoate potassium, and glibenclamide, 24 hours after permanent ligation of both common carotid arteries, using the Vestal rat model of vascular dementia The combination was administered intravenously and then twice daily for three weeks.

[0657] therapy group

[0658] The treatment groups ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a combination comprising (a) a sulfonylurea; and (b) at least one of the following components: (i) an insulin modulator and (ii) an aldosterone antagonist, for example in combinations comprising (a) glibenclamide or a structural or functional analog thereof; and (b) at least one of the following components: (i) exenatide or a structural or functional analogue thereof or a pharmaceutically acceptable salt thereof; and (ii) potassium canlylate or a structural or functional analogue thereof. The combination is suitable for use in the treatment of stroke and other neurodegenerative conditions, as well as in the treatment and / or prevention of ischemia and / or reperfusion injury of various important organs, including the brain and heart. Other aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising the combination according to the invention, as well as methods of treatment using the same.

Description

technical field [0001] The present invention provides a combination suitable for use in the treatment of stroke and neurodegenerative disorders and in the treatment and / or prevention of ischemia and / or reperfusion injury of various vital organs including the brain and heart. [0002] Other aspects of the invention relate to pharmaceutical products and pharmaceutical compositions comprising said combinations, and methods of treatment using them. Background technique [0003] Strokes are caused by a lack of blood flow in the brain (ischemic stroke) or by bleeding in the brain (hemorrhagic stroke), both of which lead to the death of brain cells. According to the World Health Organization, stroke was responsible for approximately 6 million deaths in 2016 and is the second leading cause of death globally. According to the Global Burden of Disease study ("Global Burden of Disease Study", Johnson CO et al., Lancet Neurol. 2019; 18: 439-58), there were 13.7 million new stroke cases...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/64A61K38/22A61K31/565A61P9/10A61P25/00A61P25/28A61P9/02A61P25/16A61P25/14
CPCA61K45/06A61K31/64A61K38/22A61K31/565A61P9/10A61P25/00A61P25/28A61P9/02A61P25/16A61P25/14A61K2300/00A61K38/26A61K31/569A61K31/4353A61K31/575A61K31/585
Inventor 乔治·沃吉特兹斯
Owner GENESIS PHARMA SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com